Alzamend Neuro, Inc.
General ticker "ALZN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.3M (TTM average)
Alzamend Neuro, Inc. does not follow the US Stock Market performance with the rate: -27.1%.
Estimated limits based on current volatility of 3.1%: low 2.04$, high 2.17$
Factors to consider:
- Earnings expected soon, date: 2025-12-10 bmo
- Total employees count: 7 (0.0%) as of 2024
- Top business risk factors: Regulatory and compliance, Commercialization challenges, Litigation risks, Management conflicts, Operational and conduct risks
- Price in estimated range
- Earnings for 15 months up through Q1 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-04-30 to 2026-04-30
- 2024-04-30 to 2025-04-30 estimated range: [5.60$, 42.47$]
- 2025-04-30 to 2026-04-30 estimated range: [1.45$, 11.75$]
Financial Metrics affecting the ALZN estimates:
- Negative: with PPE of -1.0 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -3.86 <= 0.33
- Negative: negative Net income
- Negative: Shareholder equity ratio, % of -410.74 <= 18.93
- Negative: negative Industry operating cash flow (median)
- Negative: -0.75 < Inventory ratio change, % of 0
- Negative: negative Industry operating income (median)
Short-term ALZN quotes
Long-term ALZN plot with estimates
Financial data
| YTD | 2022-04-30 | 2023-04-30 | 2024-04-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $12.32MM | $14.87MM | $9.94MM |
| Operating Income | $-12.32MM | $-14.87MM | $-9.94MM |
| Non-Operating Income | $-0.04MM | $-0.01MM | $-0.01MM |
| Interest Expense | $0.05MM | $0.01MM | $0.01MM |
| R&D Expense | $5.20MM | $7.45MM | $6.46MM |
| Income(Loss) | $-12.36MM | $-14.88MM | $-9.95MM |
| Profit(Loss)* | $-12.36MM | $-14.88MM | $-9.95MM |
| Stockholders Equity | $13.35MM | $3.05MM | $-2.59MM |
| Assets | $14.52MM | $5.92MM | $0.63MM |
| Operating Cash Flow | $-6.61MM | $-8.92MM | $-8.27MM |
| Capital expenditure | $0.11MM | $0.00MM | $0.15MM |
| Investing Cash Flow | $-0.11MM | $0.00MM | $-0.15MM |
| Financing Cash Flow | $18.85MM | $0.00MM | $3.65MM |
| Earnings Per Share** | $-4.17 | $-4.58 | $-2.94 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.